Phase 2
Completed N=106
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Source: ClinicalTrials.gov NCT01102231 ↗Enrolled (actual)
106
Serious AEs
25.5%
Results posted
Feb 2021
Primary outcomePrimary: Disease-Control Rate — 89 Participants
Summary
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and pemetrexed) with concurrent radiotherapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Disease-Control Rate |
89 | — |
| SECONDARY 18-month Overall Survival Rate |
42.4 | — |
| SECONDARY Progression Free Survival |
14.4 | — |
Eligibility Criteria
Inclusion Criteria
- non-squamous stage III non-small cell lung cancer
- measurable disease (RECIST 1.1)
- ECOG performance status 0-1
- normal organ and marrow function
Exclusion Criteria
- prior chest radiation therapy
- history of any cancer other than NSCLC (except non-melanoma skin cancer or carcinoma in situ of the cervix) within the last five years.
- Prior therapy with known specific inhibitors of the EGFR.
- history of severe allergic reaction to prior therapy with monoclonal antibodies
Data sourced from ClinicalTrials.gov (NCT01102231). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.